Login / Signup

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study.

Su-Gang GongLan WangBigyan PudasainiPing YuanRong JiangQin-Hua ZhaoJing HeRui ZhangWen-Hui WuJin-Ming LiuCai-Cun Zhou
Published in: Canadian respiratory journal (2018)
It is safe for stable PAH patients to transition from ambrisentan to bosentan without hemodynamic or hematologic deterioration.
Keyphrases
  • pulmonary arterial hypertension
  • pulmonary artery
  • pulmonary hypertension
  • end stage renal disease
  • chronic kidney disease
  • ejection fraction
  • peritoneal dialysis
  • prognostic factors
  • polycyclic aromatic hydrocarbons